An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
VistaGen Therapeutics (NASDAQ: VTGN) has scheduled a conference call for June 23, 2022, at 2:00 PM PT to discuss its fiscal year 2022 financial results, ending March 31, 2022. The call will also cover recent achievements and future milestones. The company is focused on advancing therapeutics for anxiety and depression, particularly its lead candidate, PH94B, a nasal spray currently in Phase 3 trials in the U.S. Results are expected in 2022. If successful, PH94B could become the first FDA-approved rapid treatment for social anxiety.
Positive
Conference call scheduled for June 23, 2022, to discuss financial results and milestones.
Lead candidate PH94B is in Phase 3 trials, with results anticipated in 2022.
Negative
None.
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--
VistaGen Therapeutics, Inc. (NASDAQ: VTGN) a late clinical-stage, central nervous system (CNS)-focused biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression, and other CNS disorders, today announced it will host a conference call and webcast on Thursday, June 23, 2022, at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) to report its financial results for fiscal year 2022 ending on March 31, 2022 and provide a review of recent achievements and anticipated upcoming milestones.
Event: VistaGen Therapeutics Fiscal Year 2022 Financial Results Conference Call
Date:Thursday, June 23, 2022 Time:2:00 pm Pacific Time (5:00 pm Eastern Time)
US Dial-in (Toll Free): 1-877-407-9716
TOLL/International Dial-in: 1-201-493-6779
Conference ID: 13729400
Webcast:https://viavid.webcasts.com/starthere.jsp?ei=1544875&tp_key=fd5623fb33
An audio webcast of the conference call will also be available via the link provided above. Participants should access this webcast site 10 minutes before the start of the call. In addition, a telephone playback of the call will be available after approximately 5:00 pm Pacific Time on Thursday, June 23, 2022. To listen to the replay, call toll free 1-844-512-2921 within the United States or 1-412-317-6671 when calling internationally (toll). Please use the replay PIN number 13729400.
About VistaGen
VistaGen Therapeutics (Nasdaq: VTGN) is a late clinical-stage, CNS-focused biopharmaceutical company striving to transform the treatment landscape for individuals living with anxiety, depression, and other CNS disorders. The Company is advancing therapeutics with the potential to be faster-acting, and with fewer side effects and safety concerns, than those that are currently available. VistaGen’s clinical-stage candidates are targeting multiple forms of anxiety and depression. They belong to a new class of drugs known as pherines, which are odorless, neuroactive steroids that bind to distinct receptors on chemosensory neurons in the nasal passages and can impact the limbic amygdala without systemic uptake or direct activity on CNS neurons in the brain. VistaGen’s lead candidate, PH94B, is a nasally administered spray currently in multiple Phase 3 trials in the U.S., with results anticipated in 2022. Should ongoing Phase 3 studies be successful, PH94B has the potential to be the first FDA-approved, fast-acting, acute treatment of anxiety for adults with social anxiety disorder. VistaGen is passionate about transforming mental health care and redefining what is possible in the treatment of anxiety and depression. Connect at www.VistaGen.com.
